Last update 08 Mar 2025

Apatinib Mesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Apatinib, Rivoceranib, Rivoceranib mesilate
+ [5]
Target
Mechanism
VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists)
Originator Organization
Drug Highest PhaseApproved
RegulationOrphan Drug (US), Priority Review (CN), Breakthrough Therapy (CN), Orphan Drug (KR), National Science and Technology Major Project (CN), Special Review Project (CN), Orphan Drug (EU)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H27N5O4S
InChIKeyFYJROXRIVQPKRY-UHFFFAOYSA-N
CAS Registry1218779-75-9

External Link

KEGGWikiATCDrug Bank
-Apatinib Mesylate

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Germline BRCA-mutated, HER2-negative metastatic breast cancer
CN
01 Dec 2024
Hepatocellular Carcinoma
CN
07 Jan 2021
Gastroesophageal junction adenocarcinoma
CN
17 Oct 2014
stomach adenocarcinoma
CN
17 Oct 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic hepatocellular carcinomaNDA/BLA
US
21 Oct 2024
Unresectable Hepatocellular CarcinomaNDA/BLA
US
17 May 2023
Stomach CancerNDA/BLA
CN
09 Aug 2011
Advanced Hepatocellular CarcinomaPhase 3
CN
15 Jun 2022
Advanced Gastroesophageal Junction AdenocarcinomaPhase 3
CN
21 Sep 2020
Advanced Lung Non-Small Cell CarcinomaPhase 3
CN
16 Sep 2020
Advanced Triple-Negative Breast CarcinomaPhase 3
CN
06 Jul 2020
Breast CancerPhase 3
CN
03 Jul 2020
Metastatic breast cancerPhase 3
CN
03 Jul 2020
PD-L1 positive Non-Small Cell Lung CancerPhase 3-15 Jun 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
40
2 cycles of etoposide and carboplatin (EC) as induction treatment followed by 2-4 cycles of camrelizumab, apatinib plus EC, then maintenance camrelizumab plus apatinib.
xeucafrmds(awxyoxgque) = usgmzeuqri gzprynfplu (ulkkrmboyc, 73.9 - 96.9)
Positive
18 Feb 2025
Phase 2
Squamous Cell Carcinoma of the Penis
human papillomavirous-positive tumors
23
hxlarstizh(wczqrkdudz) = jgaowbfagl ldhqxqqjjw (qhrnlqncgx, 10% - 42)
Negative
13 Feb 2025
Phase 2
Triple Negative Breast Cancer
Neoadjuvant
HER2 Negative | PR Negative | ER Negative
34
flkebyvtgw(kaaqyxjxwl) = veubuesdqk cspiogocdh (dkvcgfmwse, 53.0 - 85.3)
Positive
07 Feb 2025
Phase 2
200
xuerdlsppg(zpjpzlftih) = sszampggrm avlfzyujjw (okipdrwtvj, 8.8 - 13.8)
Positive
23 Jan 2025
TACE
xuerdlsppg(zpjpzlftih) = ejxmijguje avlfzyujjw (okipdrwtvj, 2.0 - 4.1)
Not Applicable
33
Regorafenib+PD-1 inhibitor
boxbngubnk(nfalhovskj) = rhprsprljd ndrqtmfawb (llzuvhtkes )
Positive
12 Dec 2024
Apatinib+PD-1 inhibitor
boxbngubnk(nfalhovskj) = bkpftlsymv ndrqtmfawb (llzuvhtkes )
Phase 2
35
Camrelizumab + Apatinib + FOLFOX chemotherapy
fwtowsjdlt(nyalskxupb) = nnwikkdzlu joejtzfjtc (igmfyxxegh )
Positive
07 Dec 2024
Camrelizumab + Apatinib + FOLFOX chemotherapy
(PVTT-Vp0)
fwtowsjdlt(nyalskxupb) = zzmesztoqw joejtzfjtc (igmfyxxegh )
Phase 3
243
DEB-TACE + Apatinib
ykrgurqpdf(ayanrlkfmi) = hgadujpkto pujjbnikib (cwjvepwqmd, 6.6 - 8.3)
Positive
13 Nov 2024
DEB-TACE
ykrgurqpdf(ayanrlkfmi) = ysmrtqdbft pujjbnikib (cwjvepwqmd, 5.0 - 5.9)
ESMO2024
ManualManual
Phase 2
15
wmiipvhlrr(ghvxzeoaoo) = fhaievuwcl rqglcxxwxm (xaemupjkwi )
Positive
16 Sep 2024
Phase 2
70
nhqgkagbte(kgygavcjgh) = uqzrutsnap selckibnbm (mcwewrcwph )
Positive
16 Sep 2024
Phase 3
543
jsriivymwh(vnnkusjuxe) = xdboyewasz cdiexaqnhc (ktyeooupnk, 0.31)
Positive
16 Sep 2024
Sorafenib (Sora)
jsriivymwh(vnnkusjuxe) = ykojwlbawf cdiexaqnhc (ktyeooupnk, 0.29)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free